Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 13/20 | 0.36 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983941 | 0.91 | ADRA1A (0.35) | KLKB1CYP3A4CYP2C8CYP2C9CNR2 | |
| SCHEMBL13842777 | 0.87 | PTGER4 (0.35) | KLKB1FSCN1PTGER4PIK3CDPIK3CA | |
| SCHEMBL3986668 | 0.85 | PTGDR2 (0.40) | PTGER4PIK3CA | |
| SCHEMBL3987572 | 0.84 | P2RX7 (0.36) | FSCN1CYP3A4CYP2C9PTGER4P2RX7 | |
| SCHEMBL3989255 | 0.83 | MAOB (0.35) | FSCN1PTGER4PIK3CAP2RX7 | |
| SCHEMBL3991213 | 0.83 | TRAP1 (0.34) | FSCN1PTGER4PIK3CAP2RX7 | |
| SCHEMBL13842722 | 0.83 | P2RX7 (0.35) | FSCN1PTGER4P2RX7 | |
| SCHEMBL3985632 | 0.82 | DCTPP1 (0.35) | FSCN1PTGER4P2RX7 | |
| SCHEMBL3985744 | 0.82 | P2RX7 (0.35) | FSCN1PTGER4P2RX7 | |
| SCHEMBL3987232 | 0.81 | PTGER4 (0.35) | FSCN1CYP2C9PTGER4PIK3CACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | claimed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | claimed |
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | KLKB1 3445/4885FSCN1 4865/4885CYP3A4 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.